Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP0601
- Development stage
- Preclinical
- Lead developer
- Scienpharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SCP0601 is a preclinical-stage small molecule dual inhibitor of AXL (Tyrosine-protein kinase receptor UFO) and c-Met (Hepatocyte growth factor receptor), developed by Shanghai Scienpharm and its subsidiary Fujian Boyue Pharmaceutical Technology. Both AXL and c-Met are receptor tyrosine kinases that are frequently overexpressed or mutated in various cancers, contributing to tumor cell proliferation, survival, metastasis, and resistance to targeted therapies. By simultaneously targeting both pathways, SCP0601 aims to overcome resistance mechanisms and provide a more effective therapeutic option for patients with solid tumors.
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on SCP0601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP0601.